PEMETREXED ZENTIVA 25mg / ml concentrate for solution for infusion medication leaflet

L01BA04 pemetrexeda • Antineoplastic and immunomodulating agents | Antimetabolites | Folic acid analogues

Pemetrexed is a chemotherapy agent used in the treatment of lung cancer and malignant pleural mesothelioma. It works by inhibiting enzymes involved in DNA and RNA synthesis, thereby preventing tumor cell growth.

The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and take folic acid and vitamin B12 supplements to reduce the risk of side effects.

Patients should be aware of potential side effects, such as fatigue, nausea, or decreased blood cell counts. It is important to inform the doctor of any unusual symptoms.

Common side effects include fatigue, nausea, and anemia. In rare cases, severe reactions such as hematologic toxicity or allergic reactions may occur. Patients should be informed of these risks before use.

General data about PEMETREXED ZENTIVA 25mg / ml

Substance: pemetrexeda

Date of last drug list: 10-04-2026

Commercial code: W64298002

Concentration: 25mg / ml

Pharmaceutical form: concentrate for solution for infusion

Quantity: 1

Product type: generic

Price: 2927.67 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: SYNTHON HISPANIA S.L. - SPANIA

Holder: ZENTIVA, K.S. - REPUBLICA CEHA

Number: 10503/2018/02

Shelf life: 2 years-after packing for marketing;after openinga flac.-it is used immediately

Concentrations available for pemetrexeda

1000mg, 100mg, 10mg/ml, 25mg/ml, 500mg

Other substances similar to pemetrexeda

Compensation lists for PEMETREXED ZENTIVA 25mg / ml ZENTIVA

NHP 3 (C2) - NHP oncology

Price

Copayment

Patient

2927.67 RON

940.46 RON

1987.21 RON